Answers are grounded in this paper and cite their sources.
Review highlights induced proximity strategies targeting androgen receptors in metastatic castration-resistant prostate cancer, suggesting a path to overcome treatment resistance.
Metastatic castration-resistant prostate cancers (mCRPC) remain dependent on androgen receptor (AR) signaling despite resistance to androgen-deprivation and AR-targeted therapies. Induced proximity-based therapeutics employ event-driven pharmacology to target AR, potentially overcoming resistance mechanisms. Herein, we highlight recent advances in induced proximity strategies targeting AR in mCRPC.
No takes yet. Share an insight, caveat, or question.
Ching et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: